GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vor Biopharma Inc (NAS:VOR) » Definitions » 5-Year EBITDA Growth Rate

Vor Biopharma (Vor Biopharma) 5-Year EBITDA Growth Rate : -31.20% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Vor Biopharma 5-Year EBITDA Growth Rate?

Vor Biopharma's EBITDA per Share for the three months ended in Dec. 2023 was $-0.40.

During the past 3 years, the average EBITDA Per Share Growth Rate was -13.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -31.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Vor Biopharma was -13.90% per year. The lowest was -54.00% per year. And the median was -40.40% per year.

Competitive Comparison of Vor Biopharma's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Vor Biopharma's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vor Biopharma's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vor Biopharma's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Vor Biopharma's 5-Year EBITDA Growth Rate falls into.


Vor Biopharma 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Vor Biopharma  (NAS:VOR) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Vor Biopharma 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Vor Biopharma's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Vor Biopharma (Vor Biopharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vor Biopharma Inc (NAS:VOR) » Definitions » 5-Year EBITDA Growth Rate
Comparable Companies
GLSI ACRV CDT TRVI DSGN ABOS ABSI NYMXF CYT GOSS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
100 Cambridgepark Drive, Suite 101, Cambridge, MA, USA, 02140
Website
https://www.vorbio.com
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
Executives
Eyal C. Attar officer: Chief Medical Officer 535 BOYLSTON STREET, BOSTON MA 02116
5am Ventures Vi, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Nathan D. Jorgensen officer: Chief Financial Officer C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Christopher Slapak officer: Chief Medical Officer C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Sadik Kassim officer: Chief Technology Officer C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Tirtha Chakraborty officer: Chief Scientific Officer C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Robert Ang director, officer: President and CEO C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
5am Partners Vi, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
David Charles Lubner director C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Puretech Health Llc 10 percent owner 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Daniella Beckman director C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
5am Opportunities I (gp), Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I, L.p. 10 percent owner 501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107